NEURAXIS INC (NRXS) Stock News

USA - NYSE Arca - NYSEARCA:NRXS - US64134X2018 - Common Stock

2.78 USD

0 (0%)

Last: 12/4/2025, 12:09:01 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

NRXS Latest News, Press Relases and Analysis

All

Press Releases

3 days ago - By: NeurAxis, Inc.

NeurAxis Secures Veterans Affairs Federal Supply Schedule Contract, Broadening Access to More Patients with Functional Abdominal Pain

17 days ago - By: Zacks Investment Research

NRXS Stock Declines Post Q3 Earnings Despite Continued Revenue Growth

23 days ago - By: NeurAxis, Inc.

NeurAxis Reports Strong Third Quarter 2025 Financial Results Driven by a 22% Growth in Revenues

24 days ago - By: Benzinga

Neuraxis Earnings Preview

a month ago - By: NeurAxis, Inc.

NeurAxis to Host Third Quarter 2025 Results and Business Update Call on Tuesday, November 11, 2025

a month ago - By: Benzinga - Mentions: IVA PMI GNTA ADIL ...

12 Health Care Stocks Moving In Friday's Pre-Market Session

4 months ago - By: Zacks Investment Research

NeurAxis Stock Down Following Q2 Earnings Despite Revenue Growth

7 months ago - By: NeurAxis, Inc.

NeurAxis Announces Closing of $5.0 Million Registered Direct Offering

a month ago - By: NeurAxis, Inc.

NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pain in Functional Dyspepsia (FD) with associated Nausea Symptoms in the Adult Patient Population

4 months ago - By: NeurAxis, Inc.

NeurAxis Reports Strong Second Quarter 2025 Financial Results Driven by a 46% Growth in Revenues

4 months ago - By: NeurAxis, Inc.

NeurAxis to Host Second Quarter 2025 Results and Business Update Call on Tuesday, August 12, 2025

6 months ago - By: NeurAxis, Inc.

NeurAxis Announces New Medical Policy Coverage with Two Health Insurers, Adding 700,000 Covered Lives

6 months ago - By: NeurAxis, Inc.

NeurAxis Achieves Critical Milestone; Secures Key Academic Society Guidelines Recommendation for Treatment of Functional Abdominal Pain (FAP) in IBS

7 months ago - By: NeurAxis, Inc.

NeurAxis Announces $5.0 Million Registered Direct Offering

7 months ago - By: Yahoo Finance - Mentions: MS COMP UNH CWGL ...

Equities Rise Intraday as Markets Weigh Macro Data, Fed Chair's Comments

7 months ago - By: Zacks Investment Research

NeurAxis Stock Gains Following Strong Q1 Earnings and FDA Milestones

7 months ago - By: NeurAxis, Inc.

NeurAxis Reports Strong First Quarter 2025 Financial Results Driven by a 39% Growth in Revenues

7 months ago - By: NeurAxis, Inc.

NeurAxis to Host First Quarter 2025 Results and Business Update Call on Monday, May 12, 2025

7 months ago - By: Zacks Investment Research - Mentions: JNJ CSCO AMZN EFX ...

Top Stock Reports for Amazon.com, Johnson & Johnson & Cisco Systems

8 months ago - By: NeurAxis, Inc.

NeurAxis to Present at the Planet MicroCap Showcase: VEGAS in partnership with MicroCapClub on Wednesday, April 23, 2025 & 1x1 Meetings on Thursday, April 24, 2025

9 months ago - By: NeurAxis, Inc.

NeurAxis Reports Strong Fourth Quarter 2024 Financial Results Driven by a 43% Increase in Revenues

9 months ago - By: NeurAxis, Inc.

NeurAxis to Host Fourth Quarter and Full Year 2024 Results and Business Update Call on Thursday, March 20, 2025

11 months ago - By: NeurAxis, Inc.

UPDATE - NeurAxis Announces New Medical Policy Coverage with a Prominent Insurer for Over Five Million Lives Across Multiple States

11 months ago - By: NeurAxis, Inc.

NeurAxis Announces New Medical Policy Coverage with Molina Healthcare for Over Five Million Lives Across Multiple States

a year ago - By: NeurAxis, Inc.

NeurAxis Inc. Issues Letter to Shareholders

a year ago - By: NeurAxis, Inc.

NeurAxis Inc. Announces Strong Preliminary Unaudited Fourth Quarter 2024 Results; Revenues Increased 50% Year-Over-Year

a year ago - By: NeurAxis, Inc.

NeurAxis Inc. to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

a year ago - By: NeurAxis, Inc.

NeurAxis Inc. Announces FDA 510(k) Clearance of RED for Testing and Evaluation of Patients with Chronic Constipation

a year ago - By: NeurAxis, Inc.

NeurAxis Reports Strong Third Quarter 2024 Financial Results Driven by a 40% Increase in Revenues

a year ago - By: NeurAxis, Inc.

NeurAxis Receives New FDA 510(K) Clearance for IB-Stim, Expanding its Addressable Market